MS in the Media - ECTRIMS 2019
ECTRIMS 2019
ECTRIMS (European Committee for Treatment and Research In Multiple Sclerosis) is the largest annual international conference devoted to basic and clinical research in multiple sclerosis. The 2019 meeting took place in Stockholm from 11 to 13 September.
The following is a small selection of coverage of information presented at the meeting.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for our free Open Door newsletter or our regular email alerts.
The course of MS
People with MS are taking longer to reach disability milestones according to Swedish research. This is probably due to lifestyle changes and better treatments and management, according to Swedish research. In Swedish clinics, "half as many patients are reaching an EDSS score of 6 [requires a walking aid] by age 64 as once did"
Source: American Journal of Managed Care
MS Trust link: Lifestyle choices
Factors in transition to SPMS
The use of disease modifying drugs and being a woman seemed to suggest a longer time before someone's MS becomes secondary progressive, according to an Italian study. People with onset over 40, with multiple symptoms and more relapses were more likely to transition sooner.
Source: MS News Today
MS Trust link: Secondary progressive MS
Hematopoietic stem cells
A debate considered issues around the use of autologous hematopoietic stem cells transplantation (AHSCT). The pro argument was that it is effective and is much safer than it was previously. The against argument accepted encouraging signs of effectiveness but argued that there is still a risk, the long-term effects aren't known and its value against a powerful disease modifying drug hasn't been tested.
Source: MS News Today
MS Trust link: Stem cell therapy
Mesenchymal stem cells
Preliminary results from trial comparing mesenchymal stem cell transplantation (MSCT) with placebo found no difference in the number of new lesions but there was a reduction of the relapse rate by about a third. Another study in Israel found that fewer people in the stem cell group showed signs of disease worsening
Source: MS News Today (the MSCT information is the bottom third of the page)
Source: MS News Today
MS Trust link: Other stem cell research being explored for MS
Safety of vaccinations
Vaccinations did not increase the risk of being diagnosed with MS according to a German review of health records. This reflects the findings of a recently published guideline by the AAN (American Academy of Neurology)
Source: MedPage Today
MS Trust link: Vaccination and immunisation
Pregnancy and DMDs
A number of presentations considered issues around the safety of disease modifying drugs during pregnancy, timing stopping treatment when trying for a family to lessen the risk of relapse, family planning and knowledge of the risks
Source: MS News Today
MS Trust link: New guidelines for pregnancy in multiple sclerosis
Relapse costs
A German study divided people with a similar EDSS score into four groups - no relapses, relapses with recovery, relapses with worsening, and progressing. Medical and non-medical costs were highest for the two relapsing groups.
Source: MS News Today
MS Trust link: Relapsing remitting MS
Ofatumumab
Two studies showed that ofatumumab reduced the relapse rate by more than half compared to Aubagio (teriflunomide). It also reduced the risk of disability progression by a third. There were fewer new lesions in the ofatumumab group
Source: Reuters
MS Trust link: Ofatumumab
Ponesimod
A study showed that ponesimod reduced the relapse rate by almost a third compared to Aubagio (teriflunomide). The drug also improved measures of fatigue
Source: MedPage Today
MS Trust link: Ponesimod
Mayzent (siponimod)
Mayzent could extend the time until someone with secondary progressive MS needs a wheelchair by 4.3 years, according to an analysis of previously reported research results.
Source: Pharma Times
MS Trust link: Mayzent (siponimod)
Conference review
Brief comments on a range of topics from the meeting including speed of diagnosis, MRI scans, ofatumumab, ponesimod, pregnancy and DMDs, gut microbiome, mesenchymal stem cells, exercise, sleep, smoking, cognition, neurofilament light chain, vaccinations, and radiologically isolated syndrome
Source: National MS Society (USA)
Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.
David's Diary- Should we all be saying yes to the Covid 19 vaccine?
18 Feb 2021 - 00:00
For the last few weeks our Enquiry Service at the MS Trust has been busy with questions about the vaccination. In his latest blog piece for the MS Trust, CEO David Martin asks the question, 'Should we all be saying yes to the Covid 19 vaccine?'
Monkey sox are back!
17 Feb 2021 - 00:00
...but this time they've gone casual! We are very excited to have partnered once again with Monkey Sox to bring you an exclusive MS Trust design.
Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.
Share
